Ziccum’s Mass Transfer drying technology LaminarPace has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application.
Find out below how LaminarPace does it, and how the system can be integrated into existing pharmaceutical manufacturing.
We’re drying biologics
So what is LaminarPace? From nebulized droplet to micronized particle, LaminarPace dries delicate biomolecules with no heat, no heat stress and no heat degradation. The result is next-generation formulations of next-generation biologics.
Integration into industrial production
LaminarPace is being developed to be integrated into industrial pharmaceutical manufacturing as a one-step, aseptic unit of production.
We are using 3D digital modeling to drive Tech Transfer, efficiencies of scale, and tailored production.
Quality by Design
Ziccum’s technology development team works continuously on optimizing the system – LaminarPace is currently in its fourth generation of development – using a rigorous Quality by Design approach.
Find out how Quality by Design minimizes risk and optimizes design and integration
3D modelling and Tech Transfer
With an extensive internal sensor array mapping LaminarPace’s drying flow, Ziccum is carrying out 3D modelling of its drying process with the ICP Institute of Computational Physics team at the Zurich University of Applied Sciences’s School of Engineering (ZHAW.)
The project is accelerating LaminarPace’s industrial development and scaleout.